Role of natural killer cells in lung cancer - Journal of Cancer Research and Clinical Oncology
- ️Dilege, Şükrü
- ️Tue Apr 03 2018
Al Omar SY, Marshall E, Middleton D, Christmas SE (2011) Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology 133(1):94–104
Andreoli C, Bassi A, Gregg EO, Nunziata A, Puntoni R, Corsini E (2015) Effects of cigarette smoking on circulating leukocytes and plasma cytokines in monozygotic twins. Clin Chem Lab Med 53(1):57–64
Anton-Culver H, Chang J, Bray F, Znaor A, Stevens L, Eser S et al (2016) Cancer burden in four countries of the Middle East Cancer Consortium (Cyprus; Jordan; Israel; Izmir Turkey) with comparison to the United States surveillance; epidemiology and end results program. Cancer Epidemiol 44:195–202
Bauer S et al (1999) Activation of natural killer cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727–730
Boutet P et al (2009) Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC class I‑related chain B protein. J Immunol 182:49–53
Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G (2008) Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(−) cells and display an impaired capability to kill tumor cells. Cancer 112(4):863–875
Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100(7):4120–4125
Cooper MA, Fehniger TA, Caligiuri MA (2001) The biology of human natural killer-cell subsets. Trends Immunol 22:633–640
Cui F, Ji J, Lv H, Qu D, Yu C, Yang Y, Xu Y (2013) Immune responsiveness in a mouse model of combined adoptive immunotherapy with NK and dendritic cells. J Cancer Res Ther 9(Suppl):S162–S168
De Vita F, Orditura M, Galizia G, Romano C, Roscigno A, Lieto E, Catalano G (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117:365–373
Deniz G, van de Veen W, Akdis M (2013) Natural killer cells in patients with allergic diseases. J Allergy Clin Immunol 132(3):527–535
Ding X, Cao H, Chen X, Jin H, Liu Z, Wang G, Cai L, Li D, Niu C, Tian H, Yang L, Zhao Y, Li W, Cui J (2015) Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer. J Transl Med 13:158
Esendagli G, Bruderek K, Goldmann T, Busche A, Branscheid D, Vollmer E, Brandau S (2008) Malignant and non-malignant lung tissue areas are differentially populated by natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 59(1):32–40
Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M et al (2016) Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncoimmunology 6(1):e1163456
Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Münz C (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172(3):1455–1462
Hatanaka H, Abe Y, Kamiya T, Morino F, Nagata J, Tokunaga T, Oshika Y, Suemizu H, Kijima H, Tsuchida T, Yamazaki H, Inoue H et al (2000) Clinical implications of interleukin-10 induced by non-small-cell lung cancer. Ann Oncol 11:815–819
Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, Ueoka H, Tanimoto M, Harada M (2002) Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2. Lung Cancer 35(3):329–333
Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jersmann H, Hodge S (2014) Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol 178(1):79–85
Huang AL, Liu SG, Qi WJ, Zhao YF, Li YM, Lei B, Sheng WJ, Shen H (2014) TGF-β1 protein expression in non-small cell lung cancers is correlated with prognosis. Asian Pac J Cancer Prev 15(19):8143–8147
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (2004) Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 83:1–1438
Jin S, Deng Y, Hao JW, Li Y, Liu B, Yu Y, Shi FD, Zhou QH (2014) NK cell phenotypic modulation in lung cancer environment. PLoS One 9(10):e109976
Jonges LE, Albertsson P, van Vlierberghe RL, Ensink NG, Johansson BR, van de Velde CJ et al (2001) The phenotypic heterogeneity of human natural killer cells: presence of at least 48 different subsets in the peripheral blood. Scand J Immunol 53:103–110
Kim S, Iizuka K, Aguila HL et al (2000) In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 97(6):2731–2736
Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G et al (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 10:3699–3707
Li Yang L, Wang, Zhang Y (2016) Immunotherapy for lung cancer: advances and prospects. Am J Clin Exp Immunol 5(1):1–20
Lin M, Liang SZ, Wang XH et al (2017) Clinical efficacy of percutaneous cryoablation combined with allogenic NK cell immunotherapy for advanced non-small cell lung cancer. Immunol Res 65(4):880–887
Lowry LE, Zehring WA (2017) Potentiation of natural killer cells for cancer immunotherapy: a review of literature. Front Immunol 8:1061
Loza MJ, Perussia B (2004) The IL‑12 signature: NK cell terminal CD56+ high stage and effector functions. J Immunol 172:88–96
Lu LM, Zavitz CC, Chen B, Kianpour S, Wan Y, Stämpfli MR (2007) Cigarette smoke impairs NK cell-dependent tumor immune surveillance. J Immunol 178(2):936–943
Luna JI, Grossenbacher SK, Murphy WJ, Canter RJ (2017) Targeting cancer stem cells with natural killer cell immunotherapy. Expert Opin Biol Ther 17(3):313–324
Luppi P, Lain KY, Jeyabalan A, DeLoia JA (2007) The effects of cigarette smoking on circulating maternal leukocytes during pregnancy. Clin Immunol 122(2):214–219
Marcus A, Gowen BG, Thompson TW, Iannello A, Ardolino M, Deng W, Wang L, Shifrin N, Raulet DH (2014) Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122:91–128
Mian MF, Lauzon NM, Stampfli MR, Mossman KL, Ashkar AA (2008) Impairment of human NK cell cytotoxic activity and cytokine release by cigarette smoke. J Leukoc Biol 83:74–784
Mian MF, Pek EA, Mossman KL, St€ampfli MR, Ashkar AA (2009a) Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I: C-augmented human PBMCs. Mol Immunol 46:3108e16
Mian MF, Pek EA, Mossman KL, Stampfli MR, Ashkar AA (2009b) Exposure to cigarette smoke suppresses IL-15 generation and its regulatory NK cell functions in poly I:C-augmented human PBMCs. Mol Immunol 46:3108–3116
Mian MF, Steampfli MR, Mossman KL, Ashkar AA (2009c) Cigarette smoke attenuation of poly I: C-induced innate antiviral responses in human PBMC is mainly due to inhibition of IFNbeta production. Mol Immunol 46:825e9
Miller JS, Morishima C, McNeel DG, Patel MR, Kohrt HE, Thompson JA et al (2017) A first-in-human phase 1 study of subcutaneous outpatient recombinant human IL-15 (rhIL-15) in adults with advanced solid tumors. Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-17-2451
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE et al (2015) Molecularly targeted therapies in non small cell lung cancer annual update 2014. J Thorac Oncol 10(101):S1–S63
Moszczyński P, Zabiński Z, Moszczyński P Jr, Rutowski J, Słowiński S, Tabarowski Z (2001) Immunological findings in cigarette smokers. Toxicol Lett 118(3):121–127
Motz GT, Eppert BL, Wortham BW, Amos-Kroohs RM, Flury JL, Wesselkamper SC, Borchers MT (2010) Chronic cigarette smoke exposure primes NK cell activation in a mouse model of chronic obstructive pulmonary disease. J Immunol 184:4460–4469
National Cancer Institute (2014) Surveillance, epidemiology and end results programme. Cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed Nov 2017
Ndhlovu LC, Lopez-Vergès S, Barbour JD, Jones RB, Jha AR, Long BR, Schoeffler EC, Fujita T, Nixon DF, Lanier LL (2012) Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity. Blood 119(16):3734–3743
Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L (2001) Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 31(4):1076–1086
Peter ME, Krammer PH (2003) The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10(1):26–35
Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P (2011) Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 71(16):5412–5422
Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J (2009) CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126:458–465
Romee R et al (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease‑17 (ADAM17). Blood 121:3599–3608
Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V (2011) Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol 6(3):432–438
Sopori M (2002) Effects of cigarette smoke on the immune system. Nat Rev Immunol 2(5):372–377
Sopori ML, Gairola CC, DeLucia AJ, Bryant LR, Cherian S (1985) Immune responsiveness of monkeys exposed chronically to cigarette smoke. Clin Immunol Immunopathol 36(3):338
Specht HM, Pelzel J, Hautmann H, Huber RM, Schossow B, Molls M, Multhoff G (2014) P67. Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT)—clinical application of NK cells activated by heat shock protein 70 (Hsp70). J Immunother Cancer 2(Suppl 2):P41
Tonn T, Schwabe D, Klingemann HG et al (2013) Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy 15(12):1563–1570
Villegas FR, Coca S, Villarrubia VG, Jime´nez R, Chillo´n MJ et al (2002) Prognostic significance of tumor infiltrating natural killer cells subset CD57 inpatients with squamous cell lung cancer. Lung Cancer 35:23–28
Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331:44
World Health Organization (2012) International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed Nov 2017
Xu L, Huang Y, Tan L, Yu W, Chen D, Lu C, He J, Wu G, Liu X, Zhang Y (2015) Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. Int Immunopharmacol 29(2):635–641
Zhang G, Zhao H, Wu J, Li J, Xiang Y, Wang G, Wu L, Jiao S (2014) Adoptive immunotherapy for non-small cell lung cancer by NK and cytotoxic T lymphocytes mixed effector cells: retrospective clinical observation. Int Immunopharmacol 21(2):396–405